Clidinium Bromide

CHEMBL1200950 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
432.3 g/mol
LogP
Phase
4

The bromide salt of clidinium, an anticholinergic drug used to reduce gastrointestinal cramping and excessive secretions. This quaternary ammonium salt is poorly absorbed from the gut, limiting systemic side effects.

Molecular Weight

432.3000 g/mol

TPSA

46.50 Ų

Mechanism of Action

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2.[Br-]

InChI

InChI=1S/C22H26NO3.BrH/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,17,20,25H,12-16H2,1H3;1H/q+1;/p-1

Molecular Formula

C22H26BrNO3

HBD / HBA

1 / 4

Rotatable Bonds

5

Heavy Atoms

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The bromide salt of clidinium, an anticholinergic drug used to reduce gastrointestinal cramping and excessive secretions. This quaternary ammonium salt is poorly absorbed from the gut, limiting systemic side effects.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Clidinium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200950. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 19004. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.